Amgad Shebl

Efficacy and safety of Privigen^® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single‐arm, open‐label Phase <scp>III</scp> study (the <scp>PRIMA</scp> study)

Jean‐Marc Léger, Jan De Bleecker, Claudia Sommer et al. · Journal of the Peripheral Nervous System · 2013 · 76 citations · Full text

Medicine, Neurology, Pharmacotherapy +12

Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012

Roger Berg, Amgad Shebl, Mary Clare Kimber et al. · Transfusion · 2015 · 37 citations

Life Sciences, Hematology, Immunology +14

Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti‐blood group A and B antibodies and individual susceptibility

Orell Mielke, Stefano Fontana, Vesselina Goranova‐Marinova et al. · Transfusion · 2017 · 18 citations · Full text

Medicine, Hematology, Immunology +8

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study

Orell Mielke, Vera Bril, David R. Cornblath et al. · Journal of the Peripheral Nervous System · 2019 · 14 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +7

Isoagglutinin reduction in intravenous immunoglobulin (<scp>IgPro10</scp>, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports

Amgad Shebl, Susie Gabriel, Kristy Van Dinther et al. · Transfusion · 2020 · 10 citations · Full text

Pharmacy, Hematology, Immunology +14